Hypergammaglobulinemia

Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009;55:1517-22.

Paricaud K, Moulis G, Combis MS, Sailler L, Arlet P. Causes of protidemia above 100g/L. Eur J Intern Med. 2014;25:e123.

Doyle LM, Gundrum JD, Farnen JP, Wright LJ, Kranig JAI, Go RS. Determining Why and Which Clinicians Order Serum Protein

Electrophoresis (SPEP), Subsequent diagnoses based on indications, and clinical significance of routine follow-up: a study of patients

with monoclonal gammopathy of undetermined significance (MGUS). Blood. 2009;114:4883.

Zhao EJ, Cheng CV, Mattman A, Chen LYC. Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management. The Lancet Haematology. 2021;8:e365-75.

Bladé J. Monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;355:2765-70.

Group IMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders a report of

the International Myeloma Working Group. Br J Haematol.2003;121:749-57

Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal

gammopathy of undetermined significance. N Engl J Med.2002;346:564-9.

Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ, 3rd Colby C, et al. Prevalence and risk of progression of light-chain

monoclonal gammopathy of undetermined significance a retrospective population-based cohort study. Lancet. 2010;375:1721-8.

Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood.2012;120:4292-5.

Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, et al. Monoclonal gammopathy of clinical significance: a novel

concept with therapeutic implications. Blood. 2018;132:1478-85.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International myeloma working group updated

criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014;15:e538-48.

Dispenzieri A. Monoclonal gammopathies of clinical significance. Hematology Am Soc Hematol Educ Program. 2020;2020:380-8.

Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management. Mayo Clin Proc. 2017;92:838-50.

Leung N, Bridoux F, Nasr SH. Monoclonal gammopathy of renal significance. N Engl J Med. 2021;384:1931-41.

van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410-27.

Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal

gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc. 2010;85:945-8.

Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering

(asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582-90.

Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, et al. New criteria to identify risk of progression

in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586-92.

Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent

risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785-9.

Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma

incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59.

Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, et al. Lenalidomide plus dexamethasone for high-risk

smoldering multiple myeloma. N Engl J Med. 2013;369:438-47.

Mateos M-V, Hernández M-T, Giraldo P, de la Rubia J, de Arriba F, Corral LL, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled,

phase 3 trial. Lancet Oncology. 2016;17:1127-36.

Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38:1126-37.

Anderson K, Ismaila N, Flynn PJ, Halabi S, Jagannath S, Ogaily MS, et al. Bone-modifying agents in multiple myeloma: american

society of clinical oncology clinical practice guideline update. J Clin Oncol. 2018;36:812-8